Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Metrics to compare | CING | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCINGPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.9x | −1.8x | −0.6x | |
PEG Ratio | −0.01 | −0.01 | 0.00 | |
Price / Book | 1.3x | 0.6x | 2.6x | |
Price / LTM Sales | - | 7.7x | 3.1x | |
Upside (Analyst Target) | - | 174.3% | 53.6% | |
Fair Value Upside | Unlock | 10.5% | 8.0% | Unlock |